These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 35586006)

  • 1. Risk of SARS-CoV-2 Reinfection 18 Months After Primary Infection: Population-Level Observational Study.
    Flacco ME; Soldato G; Acuti Martellucci C; Di Martino G; Carota R; Caponetti A; Manzoli L
    Front Public Health; 2022; 10():884121. PubMed ID: 35586006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico.
    Montes-González JA; Zaragoza-Jiménez CA; Antonio-Villa NE; Fermín-Martínez CA; Ramírez-García D; Vargas-Vázquez A; Gutiérrez-Vargas RI; García-Rodríguez G; López-Gatell H; Valdés-Ferrer SI; Bello-Chavolla OY
    Front Public Health; 2023; 11():1146059. PubMed ID: 37081954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 Reinfections in Health-Care Workers, 1 March 2020-31 January 2023.
    Cegolon L; Magnano G; Negro C; Larese Filon F;
    Viruses; 2023 Jul; 15(7):. PubMed ID: 37515237
    [No Abstract]   [Full Text] [Related]  

  • 4. Risk of SARS-CoV-2 reinfection by vaccination status, predominant variant and time from prior infection: a cohort study, Reggio Emilia province, Italy, February 2020 to February 2022.
    Vicentini M; Venturelli F; Mancuso P; Bisaccia E; Zerbini A; Massari M; Cossarizza A; De Biasi S; Pezzotti P; Bedeschi E; Giorgi Rossi P; ;
    Euro Surveill; 2023 Mar; 28(13):. PubMed ID: 36995374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
    PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of reinfection and disease after SARS-CoV-2 primary infection: Meta-analysis.
    Flacco ME; Acuti Martellucci C; Baccolini V; De Vito C; Renzi E; Villari P; Manzoli L
    Eur J Clin Invest; 2022 Oct; 52(10):e13845. PubMed ID: 35904405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022.
    Bøås H; Storm ML; Tapia G; Kristoffersen AB; Løvlie AL; Størdal K; Lyngstad TM; Bragstad K; Hungnes O; Veneti L
    BMC Public Health; 2024 Jan; 24(1):181. PubMed ID: 38225588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, Risk, and Severity of SARS-CoV-2 Reinfections in Children and Adolescents Between March 2020 and July 2022 in Serbia.
    Medic S; Anastassopoulou C; Lozanov-Crvenkovic Z; Dragnic N; Petrovic V; Ristic M; Pustahija T; Tsakris A; Ioannidis JPA
    JAMA Netw Open; 2023 Feb; 6(2):e2255779. PubMed ID: 36780157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
    Nordström P; Ballin M; Nordström A
    Lancet Infect Dis; 2022 Jun; 22(6):781-790. PubMed ID: 35366962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 reinfection with Omicron variant in Shaanxi Province, China: December 2022 to February 2023.
    Zhang M; Cao L; Zhang L; Li X; Chen S; Zhang Y
    BMC Public Health; 2024 Feb; 24(1):496. PubMed ID: 38365671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study.
    Jang EJ; Choe YJ; Yun GW; Wang S; Cho UJ; Yi S; Lee S; Park YJ
    J Med Virol; 2022 Nov; 94(11):5589-5592. PubMed ID: 35879105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
    Chemaitelly H; Nagelkerke N; Ayoub HH; Coyle P; Tang P; Yassine HM; Al-Khatib HA; Smatti MK; Hasan MR; Al-Kanaani Z; Al-Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul-Rahim HF; Nasrallah GK; Al-Kuwari MG; Butt AA; Al-Romaihi HE; Al-Thani MH; Al-Khal A; Bertollini R; Abu-Raddad LJ
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 36179099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and severity of SARS-CoV-2 reinfection, a multicenter cohort study in Shanghai, China.
    Yu W; Guo Y; Hu T; Liu Y; Fan Q; Guo L; Zheng B; Kong Y; Zhu H; Yu J; Chen S; Zhang Y; Wang J; Li F; Yang F; Wang Y; Zhu Y; Huang Y; Shen Z; Ruan Y; Mao R; Zhang J
    J Med Virol; 2023 Aug; 95(8):e28997. PubMed ID: 37537950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
    Wei J; Stoesser N; Matthews PC; Khera T; Gethings O; Diamond I; Studley R; Taylor N; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
    Nat Commun; 2024 Feb; 15(1):1008. PubMed ID: 38307854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ecological study on reinfection rates using a large dataset of RT-qPCR tests for SARS-CoV-2 in Santiago of Chile.
    Acuña-Castillo C; Barrera-Avalos C; Bachelet VC; Milla LA; Inostroza-Molina A; Vidal M; Luraschi R; Vallejos-Vidal E; Mella-Torres A; Valdés D; Reyes-López FE; Imarai M; Rojas P; Sandino AM
    Front Public Health; 2023; 11():1191377. PubMed ID: 37492136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection.
    Lewis N; Chambers LC; Chu HT; Fortnam T; De Vito R; Gargano LM; Chan PA; McDonald J; Hogan JW
    JAMA Netw Open; 2022 Jul; 5(7):e2223917. PubMed ID: 35895058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS CoV-2 reinfection rate is higher in the Omicron variant than in the Alpha and Delta variants.
    Özüdoğru O; Bahçe YG; Acer Ö
    Ir J Med Sci; 2023 Apr; 192(2):751-756. PubMed ID: 35711013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity.
    Pilz S; Theiler-Schwetz V; Trummer C; Krause R; Ioannidis JPA
    Environ Res; 2022 Jun; 209():112911. PubMed ID: 35149106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis - California and New York, May-November 2021.
    León TM; Dorabawila V; Nelson L; Lutterloh E; Bauer UE; Backenson B; Bassett MT; Henry H; Bregman B; Midgley CM; Myers JF; Plumb ID; Reese HE; Zhao R; Briggs-Hagen M; Hoefer D; Watt JP; Silk BJ; Jain S; Rosenberg ES
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):125-131. PubMed ID: 35085222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.